Biotechnology company developing therapeutic candidates targeting drug-resistant and devastating cancers using ferroptosis
Randy Milby, the Chief Executive Officer and Chairman of Hillstream BioPharma, a biotechnology company developing therapeutic candidates targeting drug-resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death, and immuno-oncology targeted novel biologics joins eHealth Radio and the Cancer Information & Health News Channels.
Listen to interview with host Eric Michaels and guest Randy Milby discuss the following:
Mr. Milby previously served as Chief Executive Officer and Member of the Board of Directors at CorMedix, a publicly traded biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of inflammatory and infectious diseases. He is a seasoned executive who led the increase in market capitalization from $3M to a peak of $350M of Cormedix while improving the company’s financial position with capital raises from equity markets. He oversaw efforts to gain CE Market approval of Neutrolin® in the European Union and held increasing roles of responsibility at Goldman Sachs and Dupont Merck prior in his career.
Website: https://hillstreambio.com
Social Media Links:
Facebook: https://facebook.com/HillstreamBioPharma
Linkedin: https://linkedin.com/company/hillstream-biopharma
Twitter: https://twitter.com/HillstreamB
People also listened to this: Checkable Medical: Revolutionizing Home Healthcare and Telemedicine
Create your
podcast in
minutes
It is Free